Rivus Pharmaceuticals
Manufacturing · Virginia, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
706 B Forest St, Charlottesville, Virgin...Website
www.rivuspharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Rivus Pharmaceuticals
Rivus Pharmaceuticals, a leader in mitochondrial biology, is advancing a new class of medicines designed to address a primary driver of cardio-metabolic diseases: obesity. Harnessing the natural process of mitochondrial uncoupling, Rivus Controlled Metabolic Accelerators (CMAs) provide a new, measured approach to reducing fat throughout the body. By doing so, CMAs can reduce the risk of cardio-metabolic disease with the aim of enabling healthier lives for millions.Explore more
Rivus Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rivus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Rivus Pharmaceuticals is spiking on competitors!
Check if Rivus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Rivus Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Rivus Pharmaceuticals recently announced quarterly report
Rivus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Rivus Pharmaceuticals has new funding data
Product Launch: Get notified when Rivus Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Click to see if Rivus Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Rivus Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Rivus Pharmaceuticals
Compare insights from companies similar to Rivus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rivus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rivus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rivus Pharmaceuticals.
Rivus Pharmaceuticals financials insights
Gather financial insights about Rivus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$55M
2022
Series B
$132M
Rivus Pharmaceuticals Tech Stack
A closer look at the technologies used by Rivus Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Rivus Pharmaceuticals News & Media
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASH
Rivus Pharmaceuticals Announces First Patients Dosed in AMPLIFY Phase 2 Trial for HU6 in MASHRivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
Rivus Pharmaceuticals Announces Appointment of Pharmaceutical Veteran Jorge Bartolome as CEORivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
Phase 2 M-ACCEL trial in MASH met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groupsRivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek®
First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rivus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rivus Pharmaceuticals, a leader in mitochondrial biology, is advancing a new class of medicines designed to address a primary driver of cardio-metabolic diseases: obesity. Harnessing the natural process of mitochondrial uncoupling, Rivus Controlled Metabolic Accelerators (CMAs) provide a new, measured approach to reducing fat throughout the body. B... Read More
